Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoon, Daniel-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorMurphy, Declan-
dc.contributor.authorCostello, Anthony-
dc.contributor.otherZargar, Homayoun-
dc.contributor.otherVan den Bergh, Roderick-
dc.contributor.otherVan Bruwaene, Siska-
dc.identifier.citationThe Journal of Urology; April 2016 vol. 195, Issue 4, Supplement, Pages e281–e282en_US
dc.description.abstractINTRODUCTION AND OBJECTIVES: to assess the impact of 2012 (May) United States Preventive Services Task Force (USPTSTF) recommendation on PSA testing, prostate biopsy and prostatectomy in Australia using Medicare data. METHODS: using Medicare item numbers for PSA (66659), Prostate biopsy (37219), Prostatectomy (37210) and Prostatectomy with lymph node dissection (37211) the occurrences of each procedure was queried per 100 000 capita for consecutive financial years over the period 2000-2015. For each item number reports were also generated for all Australian states. For PSA testing the results were stratified for the three age groups of 45-54, 55-64 and 65-74 years old. RESULTS: steady decline in per capita incidences of all four item numbers assessed were observed for the three consecutive financial years since the publication of USPTSTF recommendation statement. These declines were observed across all states. The nationwide incidences of PSA testing for 2012, 2013, 2014 and 2015 financial years were 485, 478, 457 and 406 per 100 000 capita respectively. Similarly the nationwide incidences of prostate biopsy for 2012, 2013, 2014 and 2015 financial years were 120, 110, 96 and 77 per 100 000 capita respectively. These declines were observed for all the three age groups assessed. CONCLUSIONS: Since the introduction of USPTSTF recommendation statement there has been a steady decline in per capita incidences of PSA testing, prostate biopsy and prostatectomy based on the Australian Medicare data. Whether these declines are in the right direction toward reduction in over diagnosis and over treatment of clinically insignificant prostate cancer or stage migration toward more locally advanced disease due to lost opportunity in diagnosing and treating early clinically significant prostate cancer will remain to be seen.en_US
dc.subjectUnited States Preventive Services Task Forceen_US
dc.subjectPSA Testingen_US
dc.subjectProstate Biopsyen_US
dc.subjectMedicare Dataen_US
dc.subjectRobotic Surgery, Epworth HealthCare, Melbourne, VIC, Australiaen_US
dc.subjectAustralian Prostate Cancer Research Centre, Epworth Richmond Hospital, Melbourne, Australia.en_US
dc.subjectUroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleMP25-09: The Impact Of United States Preventive Services Task Force (USPTSTF) Recommendation On PSA Testing In Australia.en_US
dc.typeConference Posteren_US
dc.description.affiliatesDepartment of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.en_US
dc.description.affiliatesDepartment of Urology, University of Leuven, Belgium.en_US
dc.description.affiliatesDepartment of Surgery, University of Melbourne, Victoria, Australia.en_US
dc.description.affiliatesDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.type.studyortrialComparative Studyen_US
dc.description.conferencenameThe American Urological Association Annual Meeting, 06 May 2016 - 10 May 2016.en_US
dc.description.conferencelocationSan Diego Convention Center, 111 W. Harbor Drive, San Diego, CA 92101.en_US
Appears in Collections:Cancer Services
Epworth Prostate Centre
UroRenal, Vascular

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.